Literature DB >> 16442283

Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors.

Andrew Morrell1, Smitha Antony, Glenda Kohlhagen, Yves Pommier, Mark Cushman.   

Abstract

A method has been developed that relies on a two-step, one-pot condensation between phthalide and 2-carboxybenzaldehydes to provide benz[d]indeno[1,2-b]pyran-5,11-diones in a multi-gram fashion. Treatment of these compounds with a primary amine allows rapid access to various N-substituted indenoisoquinolines, whose in vitro anticancer activity and topoisomerase I inhibition have been evaluated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16442283     DOI: 10.1016/j.bmcl.2006.01.008

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors.

Authors:  Trung Xuan Nguyen; Andrew Morrell; Martin Conda-Sheridan; Christophe Marchand; Keli Agama; Alun Bermingham; Alun Bermingam; Andrew G Stephen; Adel Chergui; Alena Naumova; Robert Fisher; Barry R O'Keefe; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-04-26       Impact factor: 7.446

2.  Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-11-23       Impact factor: 7.446

3.  Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.

Authors:  Daniel E Beck; Monica Abdelmalak; Wei Lv; P V Narasimha Reddy; Gabrielle S Tender; Elizaveta O'Neill; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-04-24       Impact factor: 7.446

4.  7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Sean DeGuire; Andrew Morrell; Keli Agama; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-08-08       Impact factor: 7.446

5.  Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.

Authors:  Katherine E Peterson; Maris A Cinelli; Andrew E Morrell; Akhil Mehta; Thomas S Dexheimer; Keli Agama; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

6.  Three-component synthesis of functionalized 5-oxo-4,5-dihydroindeno[1,2-b]pyrans.

Authors:  Issa Yavari; Mehdi Sirouspour; Sanaz Souri
Journal:  Mol Divers       Date:  2006-06-16       Impact factor: 2.943

7.  A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

8.  Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).

Authors:  Martin Conda-Sheridan; P V Narasimha Reddy; Andrew Morrell; Brooklyn T Cobb; Christophe Marchand; Keli Agama; Adel Chergui; Amélie Renaud; Andrew G Stephen; Lakshman K Bindu; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-12-21       Impact factor: 7.446

9.  Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.

Authors:  Martin Conda-Sheridan; Eun-Jung Park; Daniel E Beck; P V Narasimha Reddy; Trung X Nguyen; Bingjie Hu; Lian Chen; Jerry J White; Richard B van Breemen; John M Pezzuto; Mark Cushman
Journal:  J Med Chem       Date:  2013-03-08       Impact factor: 7.446

10.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.